FDA OKs 1st hay fever allergy immunotherapy tablet

Published



TRENTON, N.J. (AP) — The Food and Drug Administration said Wednesday that it has approved the first tablet in the U.S. for gradually reducing hay fever symptoms, an alternative to months of weekly doctor visits for uncomfortable allergy-desensitizing shots.

Oralair was approved for patients ages 10 through 65. It’s made by France’s Stallergenes SA, a leader in immunotherapy medicines that dissolve under the tongue.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.